Your browser doesn't support javascript.
loading
Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C / Results of treatment with peginterferon plus ribavirin in patients with chronic hepatitis C
Pizarro, Carolina; Venegas, Mauricio; Hola, Karen; Smok, Gladys; Brahm, Javier.
  • Pizarro, Carolina; Hospital Clínico Universidad de Chile. Sección de Gastroenterología. Santiago. CL
  • Venegas, Mauricio; Hospital Clínico Universidad de Chile. Sección de Gastroenterología. Santiago. CL
  • Hola, Karen; Hospital Naval Almirante Nef. Viña del Mar. CL
  • Smok, Gladys; Hospital Clínico Universidad de Chile. Departamento de Anatomía Patológica. Santiago. CL
  • Brahm, Javier; Hospital Clínico Universidad de Chile. Sección de Gastroenterología. Santiago. CL
Rev. méd. Chile ; 139(6): 704-709, jun. 2011. ilus
Artigo em Espanhol | LILACS | ID: lil-603114
ABSTRACT

Background:

The current treatment recommendation for chronic hepatitis C virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks, depending on the viral genotype. The aim of the therapy is to obtain a sustained virological response.

Aim:

To report our experience in the treatment of chronic hepatitis C. Material and

Methods:

Analysis of 52 patients treated between September 2000 and June 2009. Patients with genotype 1 or 5 were treated with peginterferon alpha 2a (180 ug/week) and ribavirin (1000 mg/day for those weighing less than 75 kg and 1200 mg/day for those weighing more than 75 kg) during 48 weeks. Patients with genotypes 2 and 3 were treated for 24 weeks with the same dose of peginterferon and ribavirin 800 mg /day.

Results:

Viral genotypes 1, 2, 3 and 5 were present in 81, 4, 11 and 4 percent of patients, respectively. Twenty four patients (46 percent), 18 with genotype 1, achieved a sustained viral response. Age was the only variable that infl uenced the response to treatment.

Conclusions:

Approximately half of the patients with chronic hepatitis C, achieve a sustained viral response with peginterferon and ribavirin.
Assuntos


Texto completo: DisponíveL Índice: LILACS (Américas) Assunto principal: Antivirais / Polietilenoglicóis / Ribavirina / Interferon-alfa / Hepatite C Crônica Tipo de estudo: Guia de Prática Clínica Limite: Adulto / Idoso / Feminino / Humanos / Masculino País/Região como assunto: América do Sul / Chile Idioma: Espanhol Revista: Rev. méd. Chile Assunto da revista: Medicina Ano de publicação: 2011 Tipo de documento: Artigo País de afiliação: Chile Instituição/País de afiliação: Hospital Clínico Universidad de Chile/CL / Hospital Naval Almirante Nef/CL

Similares

MEDLINE

...
LILACS

LIS


Texto completo: DisponíveL Índice: LILACS (Américas) Assunto principal: Antivirais / Polietilenoglicóis / Ribavirina / Interferon-alfa / Hepatite C Crônica Tipo de estudo: Guia de Prática Clínica Limite: Adulto / Idoso / Feminino / Humanos / Masculino País/Região como assunto: América do Sul / Chile Idioma: Espanhol Revista: Rev. méd. Chile Assunto da revista: Medicina Ano de publicação: 2011 Tipo de documento: Artigo País de afiliação: Chile Instituição/País de afiliação: Hospital Clínico Universidad de Chile/CL / Hospital Naval Almirante Nef/CL